Get the Stockscreener App
16.34
9.62%
-1.74
After Hours:
16.35
0.01
+0.06%
Sanara Medtech Inc stock is traded at $16.34, with a volume of 306.63K.
It is down -9.62% in the last 24 hours and down -17.89% over the past month.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
See More
Previous Close:
$18.08
Open:
$18.14
24h Volume:
306.63K
Relative Volume:
4.88
Market Cap:
$146.19M
Revenue:
$101.90M
Net Income/Loss:
$-6.41M
P/E Ratio:
-3.7625
EPS:
-4.3429
Net Cash Flow:
$-889.00K
1W Performance:
-12.43%
1M Performance:
-17.89%
6M Performance:
-47.70%
1Y Performance:
-47.63%
1-Day Range:
$16.05
$18.32
1-Week Range:
$16.05
$19.37
52-Week Range:
$16.05
$35.95
Sanara Medtech Inc Stock (SMTI) Company Profile
Name
Sanara Medtech Inc
Sector
Industry
Phone
817-529-2300
Address
1200 SUMMIT AVE, FORT WORTH
Compare SMTI vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMTI
Sanara Medtech Inc
|
16.34 | 161.76M | 101.90M | -6.41M | -889.00K | -4.3429 |
ISRG
Intuitive Surgical Inc
|
469.98 | 167.61B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
158.27 | 44.35B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
75.26 | 36.19B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
42.67 | 34.11B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
226.31 | 33.24B | 5.40B | 1.49B | 1.78B | 10.12 |
Sanara Medtech Inc Stock (SMTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-25 | Reiterated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | H.C. Wainwright | Buy |
| May-20-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jun-30-21 | Initiated | Cantor Fitzgerald | Overweight |
Sanara Medtech Inc Stock (SMTI) Latest News
Retail Trends: Can Sanara MedTech Inc maintain sales growth2026 Technical Patterns & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Sanara MedTech Hits 52-Week Low of $17.54 Amidst Market Struggles - Markets Mojo
Sanara MedTech shares rise more than 3% despite fourth-quarter earnings miss - MSN
Sanara MedTech (SMTI) to Release Quarterly Earnings on Wednesday - Defense World
Sanara MedTech Inc. 2025 Business Overview: Surgical Product Focus, Innovation Strategy, and Regulatory Compliance - Minichart
Sanara MedTech Inc. (SMTI) Q4 earnings miss estimates - MSN
Sanara MedTech Inc (SMTI) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... By GuruFocus - Investing.com Canada
Sanara MedTech (NASDAQ: SMTI) ends THP unit, doubles down on surgery - Stock Titan
Sanara MedTech Inc (SMTI) Q4 2025 Earnings Call Highlights: Reco - GuruFocus
Targets Report: Can Sanara MedTech Inc deliver consistent dividends2026 Market Sentiment & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Sanara MedTech Reports Strong 2025 Financial Results With 19% Revenue Growth, Reaffirms 2026 Guidance - Minichart
Sanara MedTech Inc. (SMTI) Q4 and Full Year 2025 Earnings: Revenue Hits $103.1 Million With 19% Growth - Bayelsa Watch
Sanara MedTech Q4 2025 Earnings Call Transcript - MarketBeat
Sanara Medtech earnings missed by $0.52, revenue fell short of estimates - Investing.com Canada
Sanara MedTech Inc. (SMTI) Q4 Earnings: Misses on EPS, Revenue Recap - AlphaStreet
Sanara MedTech Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Sanara MedTech Q4 2025 misses EPS forecast, stock drops - Investing.com
Sanara MedTech Inc. (SMTI) Misses Q4 EPS Estimates by 215.9% - AlphaStreet
Sanara MedTech Inc. (SMTI) Q4 Earnings Miss Estimates - Yahoo Finance
Sanara Medtech Inc. Reaffirms Revenue Guidance for the Full Year Ending December 31, 2026 - marketscreener.com
Sanara MedTech stock rises over 3% despite fourth quarter miss By Investing.com - Investing.com India
Sanara MedTech Inc. Reports Fourth Quarter (Unaudited) and Full Year 2025 Financial Results; Reaffirmed Full Year 2026 Financial Guidance - The Manila Times
Sanara MedTech reports FY2025 revenue $103.1M, Q4 revenue $27.5M and Adjusted EBITDA $17.0M - TradingView
Sanara MedTech posts higher Q4 revenue, reaffirms guidance - TradingView
Sanara MedTech Inc. Reports Fourth Quarter (Unaudited) and - GlobeNewswire
Sanara MedTech Inc. (SMTI) Q4 Results Fall Short of Projections - Bitget
Sanara MedTech (SMTI) CEO receives 25,430-share restricted stock grant vesting through 2029 - Stock Titan
Sanara MedTech (SMTI) grants restricted stock to controller vesting through 2029 - Stock Titan
Sanara MedTech (SMTI) awards COO 13,956 restricted shares - Stock Titan
Sanara MedTech (SMTI) CFO awarded 12,687 restricted shares vesting 2027-2029 - Stock Titan
What To Expect From Sanara MedTech Inc (SMTI) Q4 2025 Earnings - GuruFocus
Can Sanara MedTech Inc grow without external fundingDay Trade & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Price-Driven Insight from (SMTI) for Rule-Based Strategy - Stock Traders Daily
Is Sanara MedTech Inc undervalued by DCF analysisWeekly Trend Recap & Weekly Momentum Stock Picks - baoquankhu1.vn
Sanara MedTech (NASDAQ:SMTI) Trading Up 0.8%Here's What Happened - MarketBeat
Aug Selloffs: Can Sanara MedTech Inc maintain sales growth2026 Earnings Surprises & High Accuracy Trade Alerts - baoquankhu1.vn
Sanara MedTech Inc. Announces Publication of Peer-Reviewed Study Evaluating the Economic and Clinical Value of CellerateRX® Surgical Powder in the Management of Spine Surgery Wounds - Orthopedics This Week
Sanara MedTech (SMTI) upgraded to strong buy: Here's what you should know - MSN
Sanara MedTech study shows cost savings with CellerateRX powder By Investing.com - Investing.com India
Sanara MedTech Inc. Announces Publication of Peer-Reviewed - GlobeNewswire
Sanara MedTech study shows cost savings with CellerateRX powder - Investing.com
Sanara MedTech (SMTI) Study Highlights Cost-Effectiveness of Cel - GuruFocus
Spine surgery wounds: CellerateRX study finds $3,852 saved per patient - Stock Titan
Sanara MedTech (SMTI) CEO has shares withheld to cover tax on RSU vesting - Stock Titan
(SMTI) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Sanara MedTech (SMTI) CEO corrects Form 4 to 414 tax-withheld shares - Stock Titan
Merger Talk: Can Sanara MedTech Inc navigate macro headwindsWeekly Investment Summary & Daily Momentum Trading Reports - baoquankhu1.vn
Valuation Update: Is Sanara MedTech Inc undervalued by DCF analysisRecession Risk & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Sanara MedTech Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026 - marketscreener.com
Sanara MedTech (SMTI) CEO has 491 shares withheld to cover tax on vesting - Stock Titan
Sanara MedTech Unveils 2026 Strategy in Investor Presentation - TipRanks
Sanara Medtech Inc Stock (SMTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):